Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : Launches 4008A™ Dialysis Machine in China

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/19/2019 | 05:34am EST

Enhancing dialysis service and accessibility to benefit more patients

Fresenius Medical Care, the world’s leading provider of dialysis products and services, today announced the launch of its 4008ATM dialysis machine in China. The product is exclusively designed to incorporate Fresenius Medical Care’s high-quality standards while reducing costs for health care systems, meeting the needs in emerging markets. With the launch of the 4008ATM, Fresenius Medical Care is aiming to bring quality life-sustaining dialysis treatment to more patients in China who are suffering from end-stage renal disease (ESRD).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005325/en/

Fresenius Medical Care proudly launched the 4008A dialysis machine in China today. (Photo: Business Wire)

Fresenius Medical Care proudly launched the 4008A dialysis machine in China today. (Photo: Business Wire)

ESRD is the stage in kidney disease when a person's kidneys permanently stop working properly. To stay alive, the patient will need to undergo long-term dialysis or receive a kidney transplant. Currently more than 600,000 patients in China had access to dialysis, but the estimated ESRD prevalence is much higher. It is crucial to make sure that more cost-effective solutions are available for these patients in need of life-sustaining dialysis therapy.

Harry de Wit, Chief Executive Officer of Fresenius Medical Care Asia-Pacific, said: “It is important to enhance the accessibility to quality dialysis treatment in China, where over 1.4 billion of people are living. We know from reports that unfortunately not all patients have access to dialysis treatment in China. To help tackle this health care challenge, we are very proud to introduce the 4008ATM to China.”

Meeting the needs of patients in China

“It is important to enhance the accessibility and affordability of dialysis in primary care, especially in the rural regions in China,” Mr. Alan Chen, Executive Vice President of Fresenius Medical Care, Greater China said. “As the global leader in dialysis therapies, Fresenius Medical Care is committed to providing high-quality products and services to patients, helping them to lead fulfilling lives. Recently, the Chinese Government has been encouraging the reach of quality medical resources to rural areas, in order to promote primary healthcare in those areas. In view of the needs of Chinese patients, Fresenius Medical Care is dedicated to contributing to the ‘Healthy China 2030’ initiative of the Chinese government, of which the development of professional dialysis centers is one of the initiatives. With our expertise, innovation and knowledge we are able to support China’s overarching vision and provide hope to patients and their families.”

A milestone of innovation in China

The 4008ATM dialysis machine is a major innovation and a joined outcome of the beneficial collaboration between the Fresenius Medical Care China Design Center in Shanghai and the company’s Research and Development teams in Germany.

“With the local insights and knowledge from our R&D team in China, the 4008ATM with its high level of safety and handling standards, including essential cleaning functions and battery back-up will benefit the vast numbers of dialysis patients in China. The machine is designed to be robust and easily handled, making it ideal for remote locations,” Dr. Olaf Schermeier, Chief Executive Officer for Global Research and Development at Fresenius Medical Care, said. “In the future, we will continue to innovate in China to cater for the needs of developing markets, so that more patients in the region can benefit from high-quality dialysis treatment.”

In addition to the launch of the 4008ATM, Fresenius Medical Care also announced an initiative dedicated to providing care and education to nephrologists, nursing staff and patients in areas with inadequate health care resources. With the hope of bringing patients a brighter future with a high quality of life, the company will conduct research, educational training and public lectures to convey kidney disease information and treatment management concepts to Chinese healthcare professionals and patients in rural areas in order to equip them with knowledge and care in order to bring positive changes to their lives.

ENDS

ABOUT FRESENIUS MEDICAL CARE

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,996 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 339,550 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

DISCLAIMER

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS MEDICAL CARE AG
11/18FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
11/11FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
11/04FRESENIUS MEDICAL CARE AG & CO. KGAA : Release of a capital market information
EQ
11/04FRESENIUS : Buys Colombia's CediMed in EUR40 Million Investment
DJ
11/01FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 50 of the Wp..
EQ
10/31FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section ..
EQ
10/29FRESENIUS MEDICAL CARE : beats third-quarter forecasts with strong sales of home..
RE
10/29FRESENIUS : 3Q Net Profit, Sales Grew; Backs Outlook
DJ
10/29FRESENIUS MEDICAL CARE : appoints Dr. Frank Maddux to Management Board, makes Gl..
EQ
10/29FRESENIUS MEDICAL CARE : again delivers strong organic growth in the third quart..
EQ
More news
Financials (USD)
Sales 2019 19 358 M
EBIT 2019 2 558 M
Net income 2019 1 311 M
Debt 2019 12 365 M
Yield 2019 1,76%
P/E ratio 2019 16,9x
P/E ratio 2020 14,2x
EV / Sales2019 1,77x
EV / Sales2020 1,64x
Capitalization 21 969 M
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,78  $
Last Close Price 73,41  $
Spread / Highest target 51,4%
Spread / Average Target 16,9%
Spread / Lowest Target -33,6%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer